FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2731692079> ?p ?o ?g. }

• W2731692079 endingPage "e0192312" @default.
• W2731692079 startingPage "e0192312" @default.
• W2731692079 abstract "The search for a universal filovirus vaccine that provides protection against multiple filovirus species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic vaccine should be able to provide protection to all known filovirus species and as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity and protection elicited by multivalent vaccines expressing glycoproteins (GP) from Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV) and Marburg virus (MARV). Immune responses against filovirus GP have been associated with protection from disease. The GP antigens were expressed by adenovirus serotypes 26 and 35 (Ad26 and Ad35) and modified Vaccinia virus Ankara (MVA) vectors, all selected for their strong immunogenicity and good safety profile. Using fully lethal NHP intramuscular challenge models, we assessed different vaccination regimens for immunogenicity and protection from filovirus disease. Heterologous multivalent Ad26-Ad35 prime-boost vaccination regimens could give full protection against MARV (range 75%-100% protection) and EBOV (range 50% to 100%) challenge, and partial protection (75%) against SUDV challenge. Heterologous multivalent Ad26-MVA prime-boost immunization gave full protection against EBOV challenge in a small cohort study. The use of such multivalent vaccines did not show overt immune interference in comparison with monovalent vaccines. Multivalent vaccines induced GP-specific antibody responses and cellular IFNγ responses to each GP expressed by the vaccine, and cross-reactivity to TAFV GP was detected in a trivalent vaccine expressing GP from EBOV, SUDV and MARV. In the EBOV challenge studies, higher humoral EBOV GP-specific immune responses (p = 0.0004) were associated with survival from EBOV challenge and less so for cellular immune responses (p = 0.0320). These results demonstrate that it is feasible to generate a multivalent filovirus vaccine that can protect against lethal infection by multiple members of the filovirus family." @default.
• W2731692079 created "2017-07-14" @default.
• W2731692079 creator A5007037072 @default.
• W2731692079 creator A5007812217 @default.
• W2731692079 creator A5014967648 @default.
• W2731692079 creator A5031670950 @default.
• W2731692079 creator A5033593951 @default.
• W2731692079 creator A5035352624 @default.
• W2731692079 creator A5041514461 @default.
• W2731692079 creator A5048790584 @default.
• W2731692079 creator A5050204024 @default.
• W2731692079 creator A5055083900 @default.
• W2731692079 creator A5056584041 @default.
• W2731692079 creator A5059130731 @default.
• W2731692079 creator A5061065988 @default.
• W2731692079 creator A5070545590 @default.
• W2731692079 creator A5072617088 @default.
• W2731692079 creator A5077023464 @default.
• W2731692079 creator A5077740666 @default.
• W2731692079 creator A5083611548 @default.
• W2731692079 creator A5083691880 @default.
• W2731692079 creator A5088122419 @default.
• W2731692079 creator A5089315262 @default.
• W2731692079 date "2018-02-20" @default.
• W2731692079 modified "2023-10-18" @default.
• W2731692079 title "A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates" @default.
• W2731692079 cites W1482198677 @default.
• W2731692079 cites W1614627200 @default.
• W2731692079 cites W1759518163 @default.
• W2731692079 cites W1793473106 @default.
• W2731692079 cites W1814034318 @default.
• W2731692079 cites W1842419814 @default.
• W2731692079 cites W1903310257 @default.
• W2731692079 cites W1919517754 @default.
• W2731692079 cites W1930739105 @default.
• W2731692079 cites W1965443156 @default.
• W2731692079 cites W1968487372 @default.
• W2731692079 cites W1971656628 @default.
• W2731692079 cites W1975375203 @default.
• W2731692079 cites W1986196732 @default.
• W2731692079 cites W1993413375 @default.
• W2731692079 cites W1998969688 @default.
• W2731692079 cites W2011356365 @default.
• W2731692079 cites W2019878748 @default.
• W2731692079 cites W2028303888 @default.
• W2731692079 cites W2028463307 @default.
• W2731692079 cites W2030292647 @default.
• W2731692079 cites W2059750463 @default.
• W2731692079 cites W2065559837 @default.
• W2731692079 cites W2073132779 @default.
• W2731692079 cites W2075938204 @default.
• W2731692079 cites W2076340825 @default.
• W2731692079 cites W2077149270 @default.
• W2731692079 cites W2081877186 @default.
• W2731692079 cites W2087482145 @default.
• W2731692079 cites W2093141813 @default.
• W2731692079 cites W2094993149 @default.
• W2731692079 cites W2103992594 @default.
• W2731692079 cites W2104192496 @default.
• W2731692079 cites W2105792630 @default.
• W2731692079 cites W2108709588 @default.
• W2731692079 cites W2114758065 @default.
• W2731692079 cites W2116152286 @default.
• W2731692079 cites W2117671399 @default.
• W2731692079 cites W2122087691 @default.
• W2731692079 cites W2122788553 @default.
• W2731692079 cites W2124603089 @default.
• W2731692079 cites W2125395553 @default.
• W2731692079 cites W2129715930 @default.
• W2731692079 cites W2138000140 @default.
• W2731692079 cites W2141122594 @default.
• W2731692079 cites W2152985351 @default.
• W2731692079 cites W2162358220 @default.
• W2731692079 cites W2162475821 @default.
• W2731692079 cites W2197717400 @default.
• W2731692079 cites W2206209853 @default.
• W2731692079 cites W2218103495 @default.
• W2731692079 cites W2247920240 @default.
• W2731692079 cites W2306568302 @default.
• W2731692079 cites W2342023283 @default.
• W2731692079 cites W2564361602 @default.
• W2731692079 cites W2583122899 @default.
• W2731692079 cites W2602584208 @default.
• W2731692079 cites W4210448401 @default.
• W2731692079 cites W798958370 @default.
• W2731692079 doi "https://doi.org/10.1371/journal.pone.0192312" @default.
• W2731692079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5916865" @default.
• W2731692079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29689118" @default.
• W2731692079 hasPublicationYear "2018" @default.
• W2731692079 type Work @default.
• W2731692079 sameAs 2731692079 @default.
• W2731692079 citedByCount "56" @default.
• W2731692079 countsByYear W27316920792018 @default.
• W2731692079 countsByYear W27316920792019 @default.
• W2731692079 countsByYear W27316920792020 @default.
• W2731692079 countsByYear W27316920792021 @default.
• W2731692079 countsByYear W27316920792022 @default.
• W2731692079 countsByYear W27316920792023 @default.

• next